Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience

Table 2

Estimated survival outcomes according to hormone receptor and pCR status (unobtainable).

Outcome status	Progression-free survival			Disease-free survival			Overall survival
	24-month estimate (95% CI)	Hazard ratio (95% CI)	value	24-month estimate (95% CI)	Hazard ratio (95% CI)	value	24-month estimate (95% CI)	Hazard ratio (95% CI)	value
ER-positive; ER-negative	100 (100–100); 86 (69–100)	0.25 (0.033, 1.912)	0.182	94 (84–100); 85 (66–100)	0.41 (0.067, 2.509)	0.336	100 (100–100); 96 (88–100)	0.68 (0.121, 3.761)	0.654
PgR-positive	100 (100–100)	Unob.	Unob.	100 (100–100)			100 (100–100)
PgR-negative	92 (81–100)			81 (61–100)			97 (92–100)
pCR; No pCR	94 (84–100); 98 (93–100)	1.36 (0.189, 9.777)	0.76	83 (63–100); 98 (93–100)	1.5 (0.231, 9.713)	0.672	100 (100–100); 98 (93–100)	0.63 (0.115, 3.453)	0.595